Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial
Published Online: 2017-08-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Anders Krarup-Hansen•Brian A Van Tine•Christopher W Ryan•Damon Reed•Denise K Reinke•G Thomas Budd•Giovanni Grignani•Hussein Tawbi•Isabelle Ray-Coquard•Kristen N Ganjoo•Lee D Cranmer•Mark Agulnik•Maud Toulmonde•Patrick Schöffski•Peter Hohenberger•Richard F Riedel•Robin L Jones•Sant P Chawla•Scott Okuno•Scott Schuetze•Steven Attia•Stew Kroll•Thierry Alcindor•Tillman Pearce•William D Tap•William Read•Xavier F Garcia del Muro•Zsuzsanna Papai
